Business Wire

FUJIFILM-VISUALSONICS

Share
Second University of Naples Installs World's First Vevo MD from FUJIFILM VisualSonics

FUJIFILM VisualSonics Inc. , a world leader in ultra high frequency ultrasound imaging systems and subsidiary of FUJIFILM SonoSite, Inc., today announced a significant milestone in its history with the installation of the first Vevo® MD Ultra High Frequency (UHF) clinical ultrasound system at the Second University of Naples in Italy. With multiple successes in preclinical research over the last decade, the Vevo® MD is FUJIFILM VisualSonics’ first foray into the clinical market.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160609006365/en/

According to Dr. Roberto Grassi, Professor of Radiology at the F. Magrassi and A. Lanzara Department at the Second University of Naples, the institution has used VisualSonics ultra high resolution ultrasound systems for preclinical studies for approximately 10 years. These UHF systems have enabled the research team to study the anatomy of small animals, such as mice and rats, with a resolution down to 30 microns. The addition of Vevo® MD—which has been in use at Second University for about a month now—brings the team’s capabilities to a whole new level and shows great potential for developing novel applications in the clinical sector.

“Preclinical research is a crucial step toward establishing clinical applications, but until the launch of the Vevo MD, there were no clinically-approved ultra high frequency systems for human studies,” said Dr. Grassi. “The Vevo MD is the world’s first CE-marked, ultra high frequency ultrasound imaging system—up to 70 MHz—for clinical use, and will transform our clinical studies, enabling visualization of superficial structures in the human body.”

First commercialized in Europe, the Vevo MD is truly a unique ultrasound system, as it operates at much higher frequencies than any conventional ultrasound system currently available. It allows medical professionals to see what they have never seen before—unparalleled image resolution down to 30 microns. The Vevo MD system is compatible with FUJIFILM VisualSonics UHF series of transducers. This patented transducer technology is capable of operating in a range of frequencies up to 70 MHz, a tremendous increase in resolution compared to conventional ultrasound systems.

The Vevo MD was designed to play a role in a range of clinical application areas including neonatology, vascular, musculoskeletal, dermatology, and other small parts that are within the first 3 cm of the body.

“The beauty of the Vevo MD is that it is non-invasive for our patients and allows us to examine the superficial strata, visualizing structures that we could not see using conventional ultrasound. It has enabled us to determine the finer upper limb damage that occur in arthritis, allowing us to investigate the effectiveness of human drug treatments for these conditions,” said Dr. Grassi. “We are now starting to perform vascular assessment of diabetic patients, and also plan to study dermatological and systemic diseases.”

About FUJIFILM VisualSonics

FUJIFILM VisualSonics, Inc., is a global leader in real time, in vivo, ultra high frequency ultrasound and photoacoustic imaging systems. With headquarters in Toronto, Canada and offices around the world, FUJIFILM VisualSonics is represented globally across an integrated sales network. FUJIFILM VisualSonics is recognized worldwide for providing cutting edge imaging technologies for the advancement of preclinical research particularly in cardiovascular, oncology, neurobiology and developmental biology areas. With the expansion of the product portfolio to include a new clinical product, FUJIFILM VisualSonics now broadens their range of imaging technologies across both preclinical and clinical markets. FUJIFILM VisualSonics is a subsidiary of FUJIFILM SonoSite, Inc. and a part of FUJIFILM Holdings Corporation. For more information, please go to: www.visualsonics.com .

FUJIFILM SonoSite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com .

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2015, the company had global revenues of $20.8 billion, at an exchange rate of 120 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com .

All product and company names herein may be trademarks of their registered owners.

Contact:

Fujifilm
Lauren Geloso, 914-789-8303
lgeloso@fujifilm.com
or
FUJIFILM VisualSonics, Inc.
Andrew Needles, 416-522-6462
aneedles@visualsonics.com
or
Kdm Communications limited, St Neots, UK
Sarah Ballard, +44 (0) 1480 405333
ideas@kdm-communications.com

Social Media:

https://www.facebook.com/VisualSonicsInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release

Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release

New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye